Amino acid surfactant with hemostatic function and synthesis method thereof

Abstract

The invention discloses an amino acid surfactant with a hemostatic function and a preparation method thereof. According to the method, tranexamic acid and long-chain fatty acyl chloride are subjected to a condensation reaction under the action of alkali, then acidification and esterification reactions are performed, the amino acid surfactant with the hemostatic function is obtained, and compared with long-chain fatty acyl tranexamic acid salt reported in the prior art, the amino acid surfactant has good lipid solubility and can be used as a hemostatic material. The preparation method has the advantages of mild reaction conditions, simple operation, simple product separation and purification and high yield, and is suitable for industrial production.

Description

Technical Field

[0001] The invention relates to a surfactant, in particular to an amino acid surfactant with hemostatic function and a synthesis method thereof, belonging to the technical field of fine chemical industry. Background Art

[0002] Amino acid surfactants are a new type of green surfactants. They not only have the properties of traditional surfactants, such as good emulsification, foaming, solubilization, wetting, and dispersion, but also have good biodegradability, low toxicity, mild and non-irritating properties, and certain antibacterial properties. At present, under the guidance of the green and safe development concept, amino acid surfactants have gradually replaced traditional surfactants and are widely used in daily chemical products, food, medicine, and chemical industries. Although amino acid surfactants have made great progress in many fields as upgraded products of traditional surfactants, the research and development of functional amino acid surfactants is still rare, and there is huge room for development.

[0003] Tranexamic acid, also known as tranexamic acid, tranexamic acid, and tranexamic acid, has a chemical name of trans-4-aminomethylcyclohexanecarboxylic acid. It can inhibit the dissolution of fibrin and exert a hemostatic effect. It is a classic hemostatic drug in surgery. It has a definite efficacy and high safety. It is widely used in clinical practice to stop bleeding after trauma or surgery. In addition, tranexamic acid is also used in daily chemical products. For example, tranexamic acid is used as an additive to prepare toothpaste with hemostatic effect. However, when solutions or creams containing hemostatic acid are used externally, due to the strong hydrophilicity and hydrogen bonding of hemostatic acid, it is difficult to pass through the skin stratum corneum barrier. It is often necessary to structurally modify the hemostatic acid to improve its percutaneous permeability and enhance its efficacy. For example, Chinese patent CN 101253148A discloses an acyloxyalkyl carbamate of trans-4-(aminomethyl)-cyclohexanecarboxylic acid, which is used as a hemostatic acid prodrug to treat bleeding or skin diseases; Chinese patent CN 105085364A discloses a tranexamic acid derivative prepared from maleic anhydride and tranexamic acid; Chinese patent CN 113952326A discloses a polyethylene glycol-modified tranexamic acid and a preparation method thereof, which can effectively prolong the efficacy time of tranexamic acid and reduce the number of medications used by patients during long-term medication. Chinese patent CN 117342971A discloses a class of fatty acyl tranexamic acid metal salts and a preparation method thereof, which are applied in the medical field and the daily chemical field, combining surfactants and coagulability, but the water solubility and fat solubility of such long-chain fatty acyl tranexamic acid metal salts are very poor. Summary of the invention

[0004] In view of the defects of amino acid surfactants in the prior art, the purpose of the present invention is to provide an amino acid surfactant with hemostatic function, which has both good surface activity and hemostatic function, can be widely used in daily chemical products and medical hemostatic products, and compared with the long-chain fatty acyl thromboxane reported in the prior art, it has good fat solubility, better transdermal permeability and better color powder dispersibility.

[0005] The second object of the present invention is to provide a method for preparing an amino acid surfactant with hemostatic function, which method has simple operation, mild conditions, low cost and is conducive to large-scale production.

[0006] In order to achieve the above technical objectives, the present invention provides an amino acid surfactant with hemostatic function, which has a structure shown in Formula 1:

[0007]

[0008] in,

[0009] R1 is a C1-C4 alkane group;

[0010] R2 is C7~C 17 of aliphatic hydrocarbon groups.

[0011] The amino acid surfactant with hemostatic function of the present invention is based on tranexamic acid as the parent structure, and a short-chain fatty hydrocarbon group is introduced on its carboxyl group, and a long-chain fatty acyl group is introduced on its amino group. It is unexpectedly found that not only its hemostatic effect is better than that of tranexamic acid, but the introduction of its long-chain fatty acyl group gives it good emulsification and dispersing functions, while the introduction of the short-chain fatty hydrocarbon group reduces the hydrophilicity of the carboxyl group, improves its fat solubility, improves its permeability to the skin, and makes it have better surface activity and hemostatic function.

[0012] In the structure of Formula 1 of the present invention, R2 is a common long-chain aliphatic hydrocarbon group, and R2 is more preferably C7-C 17 Straight chain alkyl, or C7~C 17 A branched alkyl group, or a C7-C 17 Specific examples include octyl, dodecyl, etc.

[0013] As a preferred solution, in the structure of Formula 1, R1 is methyl, ethyl, propyl, isopropyl or butyl. R1 can only be a low-carbon aliphatic group. If the carbon chain of R1 is too long, it will lose its surfactant function.

[0014] The present invention also provides a method for synthesizing an amino acid surfactant with a hemostatic function, which comprises fully dissolving tranexamic acid or a tranexamic acid salt, an alkali, an organic cosolvent and water, cooling the mixture to below 10°C, slowly dripping a fatty acid chloride to carry out an amidation reaction, and using an alkali solution to maintain the pH of the reaction system. After the fatty acid chloride is dripped, the reaction is continued for more than 1 hour, and the reaction solution is transferred to a dilute acid solution to precipitate. After the precipitate is uniformly mixed with an alcohol, an acid catalyst is added to catalyze an esterification reaction. After the reaction is completed, the alcohol is recovered by distillation, and then extracted and separated to obtain the target product.

[0015] The fatty acid chloride has a structure shown in Formula 2:

[0016]

[0017] The alcohol is a C1-C4 monohydric alcohol.

[0018] As a preferred embodiment, the base is 0.5 to 1.5 times the molar amount of tranexamic acid or tranexamic acid salt, such as sodium salt.

[0019] As a preferred solution, the mass of the tranexamic acid or tranexamic acid salt is 5-15% of the mass of water.

[0020] As a preferred solution, the mass of the organic co-solvent is 5-15% of the mass of water.

[0021] As a preferred solution, the organic co-solvent includes acetone and / or ethanol, and acetone is most preferred. The solubility of tranexamic acid or tranexamic acid salt in water can be improved by introducing a co-solvent.

[0022] As a preferred embodiment, the base is at least one of sodium hydroxide, potassium hydroxide and triethylamine, and most preferably sodium hydroxide.

[0023] As a preferred embodiment, the molar amount of the fatty acid chloride is 0.8 to 1.2 times the molar amount of tranexamic acid or tranexamic acid salt.

[0024] As a preferred solution, the acid catalyst is sulfuric acid.

[0025] As a preferred solution, the esterification reaction is carried out under the following conditions: reacting at reflux temperature for 6 to 12 hours.

[0026] The synthesis method of the amino acid surfactant with hemostatic function of the present invention is as follows:

[0027]

[0028] Compared with the prior art, the technical solution of the present invention has the following beneficial technical effects:

[0029] The amino acid surfactant with hemostatic function provided by the present invention has both surface activity and hemostatic function, and compared with long-chain fatty acyl tranexamic acid metal salts, it has good fat solubility, better percutaneous permeability, and good color powder dispersibility, and is expected to be used as an additive in daily chemical products and medical hemostatic products with hemostatic effect.

[0030] The preparation method of the amino acid surfactant with hemostatic function provided by the invention has simple operation, mild conditions, low cost and is conducive to large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is the H NMR spectrum of N-lauroyltranexamic acid.

[0032] Figure 2 This is the H NMR spectrum of ethyl N-lauroylcarbamate.

[0033] Figure 3 This is the H NMR spectrum of N-lauroylcarbamate isopropyl ester.

[0034] Figure 4 The transdermal absorption curves of different compounds. DETAILED DESCRIPTION

[0035] The following specific examples are intended to further illustrate the present invention rather than to limit the scope of protection of the claims.

[0036] Example 1

[0037] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 11.97g of lauroyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 17.51g of high-purity white solid product, with a yield of 94%. 1 H NMR (400MHz, d 6 -DMSO) δ12.00(brs,1H),7.74(s,1H),2.87(t,J=8.0Hz,2H),2.12–2.05(m,1H),2.03(t,J=8.0Hz,2H),1.8 8(d,J=12.0Hz,2H),1.70(d,J=12.0Hz,2H),1.50–1.42(m,2H),1.31–1.16(m,19H),0.93–0.83(m,5H)ppm.

[0038] Example 2

[0039] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 15°C, slowly add 11.97g of lauroyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 17.09g of high-purity white solid product, with a yield of 92%.

[0040] Example 3

[0041] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of ethanol, continue stirring and cool to 10°C, slowly add 11.97g of lauroyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 15.02g of high-purity white solid product, with a yield of 81%.

[0042] Example 4

[0043] Add 90mL of water to the reactor, add 2.00g of potassium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 11.97g of lauroyl chloride, and maintain the current pH value with 30% potassium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 16.81g of high-purity white solid product, with a yield of 91%.

[0044] Example 5

[0045] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 13.12g of lauroyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 17.80g of high-purity white solid product, with a yield of 87%.

[0046] Example 6

[0047] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 14.43g of lauroyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 18.66g of high-purity white solid product, with a yield of 92%.

[0048] Example 7

[0049] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 10.41g of octanoyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 15.52g of high-purity white solid product, with a yield of 91%.

[0050] Example 8

[0051] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 12.21g of decanoyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 17.17g of high-purity white solid product, with a yield of 92%.

[0052] Example 9

[0053] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly drop 15.04g of palmitoyl chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 21.95g of high-purity white solid product, with a yield of 93%.

[0054] Example 10

[0055] Add 90mL of water to the reactor, add 1.40g of sodium hydroxide, and after 9.43g of tranexamic acid is dissolved, add 12mL of acetone, continue stirring and cool to 10°C, slowly add 13.92g of coconut oil chloride, and maintain the current pH value with 30% sodium hydroxide aqueous solution. After the addition is completed, continue stirring for 1h, transfer to hydrochloric acid aqueous solution and stir for 1h, precipitate white solid, filter, wash with water, and dry to obtain 19.28g of high-purity white solid product, with a yield of 95%.

[0056] The methods for preparing long-chain acylcarbamate esters by esterification of the long-chain acylcarbamate obtained in Examples 1 to 10 are similar, and N-lauroylcarbamate is used as an example for explanation below.

[0057] Embodiment 11

[0058] In a 100mL round-bottomed flask, add 6.79g of the N-lauroyl tranexamic acid prepared in Example 1 and 40mL of ethanol, and stir evenly. Add 0.01g of concentrated sulfuric acid (5mol%), set up an esterification reaction dehydration device (molecular sieve dehydration), after heating reflux for 6h, stop heating and cool to room temperature. The reaction solution is distilled under reduced pressure to recover most of the ethanol, 50mL of ethyl acetate is added, and transferred to a separating funnel. The organic phase is washed with 20mL of water, 10% sodium bicarbonate solution, water and saturated common salt water in turn, dried over anhydrous sodium sulfate, and then distilled under reduced pressure to remove the solvent to obtain 6.22g of N-lauroyl tranexamic acid ethyl ester product, with a productive rate of 85%. 1 H NMR (400MHz, CDCl3) δ5.61(brs,1H),4.09(q,J=8.0Hz,2H),3.09(t,J=8.0Hz,2H),2.15(t,J=8.0Hz,2H),1.98(dd,J=12.0Hz,4.0Hz,2H),1 .80(dd,J=12.0Hz,4.0Hz,2H),1.60(t,J=8.0Hz,2H),1.44–1.33(m,4H),1.28–1.21(m,19H),1.00–0.93(m,2H),0.86(t,J=8.0Hz,3H)ppm.

[0059] Example 12

[0060] In a 100mL round-bottomed flask, add 6.79g of the prepared N-lauroyl tranexamic acid in Example 1 and 50mL of isopropanol, stir. Add 0.01g of concentrated sulfuric acid (5mol%) again, set up an esterification reaction dehydration device (molecular sieve dehydration), after reflux for 8h, stop heating and cool to room temperature. The reaction solution is distilled under reduced pressure to reclaim most of the ethanol, add 50mL of ethyl acetate, transfer to a separating funnel, the organic phase is washed with 20mL of water, 10% sodium bicarbonate solution, water and saturated common salt water successively, dried over anhydrous sodium sulfate, and then distilled under reduced pressure to remove the solvent and obtain 6.19g of N-lauroyl tranexamic acid isopropyl ester product, and the productive rate is 81%. 1 HNMR (400MHz, CDCl3) δ5.62(brs,1H),4.99–4.93(m,1H),3.09(t,J=8.0Hz,2H),2.15(t,J=8.0Hz,2H),1.97(dd,J=12.0Hz,4.0Hz,2H),1.80(dd,J=1 2.0Hz,4.0Hz,2H),1.60(t,J=8.0Hz,2H),1.48–1.32(m,4H),1.26–1.21(m ,16H),1.20(d,J=4.0Hz,6H),1.00–0.90(m,2H),0.86(t,J=8.0Hz,3H)ppm.

[0061] Example 13

[0062] Comparative test of the hemostatic function of N-lauroyl tranexamic acid ethyl ester and N-lauroyl tranexamic acid sodium obtained in Example 11:

[0063] Experimental method: 42 ICR mice that passed the quarantine were selected, half male and half female, weighing 20.4-25.6g. They were randomly divided into model control group, test group 1, 2, 3, and N-lauroyl carbamate sodium control group 1, 2, 3 according to gender and weight, with 6 mice in each group. The mice were fixed in a mouse tube, and different concentrations of test samples or saline were given at 2cm from the tip of the tail. The administration time was 30 minutes, and the administration was repeated once after an interval of 4 hours. 30 minutes after the last administration, the tail of the mouse was cut off at 1.5cm from the tip of the tail with ophthalmic scissors. When the blood naturally flowed out, the bleeding time was recorded. The blood drops were absorbed with a cotton ball weighed in advance every 10s until the bleeding stopped naturally (no blood was absorbed by the cotton ball), and the weight of the bloody cotton ball was weighed. The bleeding time of the mouse tail was recorded, and the amount of bleeding of each group of animals was calculated.

[0064] (2) Dosage design: The sample dosage is shown in Table 1.

[0065] Table 1 Trial grouping and dosage design

[0066]

[0067] (3) Test results:

[0068] (a) Effect on bleeding volume in ICR mice

[0069] As shown in Table 2, compared with the model control group, the amount of tail tip bleeding in the animals in test group 2 was significantly reduced (P<0.05), and there was no statistical difference in the amount of tail tip bleeding in the animals in test groups 1 and 3 (P>0.05).

[0070] Table 2 Bleeding volume of mice in each group ( n=6)

[0071]

[0072] (b) Effect on bleeding time of ICR mice

[0073] As shown in Table 3, compared with the model control group, the bleeding time in test group 2 was significantly reduced (P<0.01), and there was no statistical difference in the tail tip bleeding time of animals in test groups 1 and 3 (P>0.05).

[0074] Table 3 Bleeding time of mice in each group ( n=6)

[0075]

[0076] (4) Conclusion and evaluation

[0077] In order to investigate and compare the hemostatic effects of samples of different concentrations and compare them with sodium N-lauroyl tranexamic acid, this study used normal ICR mice, administered different concentrations of the test substance by tail contact method, and then cut off the tail to observe the bleeding amount and bleeding time of each group of mice, and studied the hemostatic effects of different concentrations of the test substance. The test results showed that the test substance of different concentrations administered by tail immersion contact method, with a concentration of 0.24%, could significantly reduce the amount of tail bleeding and shorten the bleeding time of ICR mice, and the hemostatic effect was significantly better than that of hemostatic acid salts.

[0078] Embodiment 14

[0079] Surface tension test of N-lauroylcarbamate ethyl ester obtained in Example 11:

[0080] (1) Experimental method: According to GB / T 22237-2008, the sample aqueous solution was prepared with double distilled water, the sample amount was 0.5 g, the sample test concentration was 0.5 g / 100 ml, and three portions were prepared in parallel. After being placed at 20°C for 1 hour, the surface tension of the aqueous solution was determined by the ring method.

[0081] (2) Experimental design

[0082] Table 4 Experimental design

[0083]

[0084] (3) Experimental results: As shown in Table 5, the test sample N-lauroylcarbamate has the ability to significantly reduce the surface tension of liquid.

[0085] Table 5 Experimental results

[0086]

[0087] (4) Conclusion and evaluation:

[0088] In order to examine the surface activity of this product, the surface tension of its aqueous solution was measured to judge the surface activity performance. From the experimental results, it can be seen that this product has good surface activity.

[0089] Embodiment 15

[0090] Referring to Examples 11 and 12, the prepared N-lauroyl tranexamic acid ethyl ester and N-lauroyl tranexamic acid isopropyl ester were applied to the following formula Table 1 as the test group, and compared with the control groups of N-lauroyl tranexamic acid sodium and tranexamic acid, respectively, using the modified Franz method to study and compare the in vitro transdermal absorption test.

[0091] Table 6

[0092]

[0093] In vitro permeation absorption test: The abdominal skin of Kunming mice was used as the permeable skin. Mice of similar weight were selected, the long hair on the abdomen was cut off, and the hair was removed after cleaning. After 24 hours of feeding, the skins were taken and the subcutaneous fat was removed. After washing with sterile saline, the skins were evaluated in a diffusion cell.

[0094] Test method: A modified Franz device (receiving pool volume of 14.5 ml, receiving pool effective contact surface of 4.14 cm) was used. 2), take the ex vivo mouse skin, with the dermis facing the Franz cell receiving cell, cover it on the receiving cell to ensure that there are no bubbles, wrap and tie it with a plastic rope along the cell mouth to prevent leakage of the receiving solution, cut off the excess skin, and place the test group sample (4.0g) close to the side of the ex vivo mouse skin stratum corneum, and seal the top of the release cell with a plastic film. Take another set of improved Franz apparatus and operate in the same way. Place the control group (4.0g) close to the side of the ex vivo mouse skin stratum corneum as a blank control. Keep the water bath constant temperature to (37°C, and stir at a constant electromagnetic speed. Take out 4ml of receiving solution from the sample receiving cell and the blank receiving cell at 0, 1, 2, 3, 4, 5, 6, and 10h, respectively, and add 50% ethanol saline to each cell. After filtering the taken receiving solution through a microporous filter membrane, take 20ul and inject it into the high performance liquid chromatography instrument for measurement. Calculate the cumulative permeation amount (Q) based on the peak area, and plot the in vitro transdermal absorption curve with time t as the horizontal axis, as shown in Figure 2. Figure 3 .

[0095] Conclusion and evaluation:

[0096] The test results show that the cumulative permeation of N-lauroyl ethyl and isopropyl ester is significantly greater than that of long-chain fatty acyl sodium tranexamic acid and tranexamic acid, indicating that this product has good transdermal permeability.

[0097] Example 16

[0098] Example 11 Obtained N-lauroylcarbamate ethyl ester lipophilicity test:

[0099] (1) Experimental method: According to SN / T2879-2011 standard, the test substance is dissolved in liquid standard fat (triglyceride mixture HB307) by stirring, and the test substance is added continuously until the mass fraction reaches a constant value through analysis and measurement, which is the saturated mass fraction of the test substance.

[0100] (1) Experimental results:

[0101] Table 7 Results of lipid solubility of substances

[0102]

[0103] As shown in Table 7, the test samples N-lauroylcarbamate ethyl ester and N-lauroylcarbamate isopropyl ester have obvious fat solubility.

Claims

1. An amino acid surfactant having a hemostatic function, characterized in that: It has the structure shown in formula 1: in, R1 is a C1-C4 alkane group; R2 is C7~C 17 of aliphatic hydrocarbon groups.

2. The amino acid surfactant having hemostatic function according to claim 1, characterized in that: R1 is methyl, ethyl, propyl, isopropyl or butyl; R2 is C7~C 17 Straight chain alkyl, or C7~C 17 A branched alkyl group, or a C7-C 17 The alkenyl group.

3. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 1 or 2, characterized in that: After fully dissolving tranexamic acid or tranexamic acid salt, alkali, organic cosolvent and water, the temperature is lowered to below 10°C, and fatty acid chloride is slowly added dropwise to carry out amidation reaction, while using alkali solution to maintain the pH of the reaction system. After the fatty acid chloride is added dropwise, the reaction is continued for more than 1 hour, and then the reaction solution is transferred to a dilute acid solution to precipitate. After the precipitate is evenly mixed with alcohol, an acid catalyst is added to catalyze the esterification reaction. After the reaction is completed, the alcohol is recovered by distillation, and then extracted and separated to obtain the target product; The fatty acid chloride has a structure shown in Formula 2: The alcohol is a C1-C4 monohydric alcohol; R2 is C7~C 17 of aliphatic hydrocarbon groups.

4. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 3, characterized in that: The base is 0.5 to 1.5 times the molar amount of tranexamic acid or tranexamic acid salt; The mass of the tranexamic acid or tranexamic acid salt is 5 to 15% of the mass of water; The mass of the organic co-solvent is 5-15% of the mass of water.

5. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 4, characterized in that: The organic co-solvent includes acetone and / or ethanol; The base is at least one of sodium hydroxide, potassium hydroxide and triethylamine.

6. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 3, characterized in that: The molar amount of the fatty acid chloride is 0.8 to 1.2 times the molar amount of tranexamic acid.

7. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 3, characterized in that: The acid catalyst is sulfuric acid.

8. The method for synthesizing an amino acid surfactant having hemostatic function according to claim 3, characterized in that: The conditions of the esterification reaction are: reacting at reflux temperature for 6 to 12 hours.

Images